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Abstract: The imidazole-based H3R antagonist 2-18 with high in vitro H3R antagonist affinity, 
excellent in vitro selectivity profile, and high in vivo H3R antagonist potency was tested for 
its anticonvulsant effect in maximal electroshock (MES)-induced convulsions in mice having 
valproic acid (VPA) as a reference antiepileptic drug (AED). Additionally, H3R antagonist 
2-18 was evaluated for its reproductive toxicity in the same animal species. The results show 
that acute systemic administration (intraperitoneal; i.p.) of H3R antagonist 2-18 (7.5, 15, 30, 
and 60 mg/kg, i.p.) significantly and dose dependently protected male as well as female mice 
against MES-induced convulsion. The protective action observed for H3R antagonist 2-18 in 
both mice sexes was comparable to that of VPA and was reversed when mice were pretreated 
with the selective H3R agonist (R)-alpha-methylhistamine (RAMH, 10 mg/kg, i.p.). Moreover, 
the results show that acute systemic administration of single (7.5, 15, 30, or 60 mg/kg, i.p.) or 
multiple doses (15×3 mg/kg, i.p.) of H3R antagonist 2-18 on gestation day (GD) 8 or 13 did not 
affect the maternal body weight of mice when compared with the control group. Furthermore, 
no significant differences were observed in the average number of implantations and resorptions 
between the control and H3R antagonist 2-18-treated group at the early stages of gestation and 
the organogenesis period. However, oral treatment with H3R antagonist 2-18 (15 mg/kg) on 
GD 8 induced a reduced number of live embryos when compared with the i.p.-treated mice. 
In addition, no significant changes in the fetal body and placental weights were observed after 
injection of H3R antagonist 2-18 with all selected doses. However, three dose groups of i.p. and 
oral 15 mg/kg on GD 13 significantly affected the placental weight when compared with control 
group. Notably, the treatment of pregnant female with the H3R antagonist 2-18 did not produce 
significant malformation in the fetus in both groups. In conclusion, the novel H3R antagonist 2-18 
proves to be a very safe compound and displays a low incidence of malformations, demonstrating 
that H3R antagonist 2-18 may have a potential future therapeutic value in epilepsy.
Keywords: H3R receptor antagonist, maximal electroshock, anticonvulsant, malformation, 
gestation, mice
Introduction
Epilepsy is one of the most common neurological disorders categorized by an unusually 
excessive neuronal discharge, which is a chief characteristic of epilepsy and is designated 
as a neurological disorder with recurring seizures.1–3 Epilepsy affects millions of people 
worldwide and is reported to affect about 5–8.4 out of 1,000 people of the population 
in the US.4 In the US alone, approximately 1.3 million women with epilepsy give birth 
to 25,000 infants each year.5 The prevalence rate of epilepsy in other regions is pos-
sibly comparable to that of the US.6 The prevalence of epilepsy in pregnant women is 
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about 0.5%.7,8 About 40% of women with epilepsy are in the 
child-bearing age group. Epileptic women are more liable to 
obstetric complications and premature labor than non-epileptic 
women.8,9 The prevalence of major malformations in infants of 
epileptic parents is twice that of the controls.10–12 Both major 
and minor malformations have been attributed to antiepileptic 
drugs (AEDs).10,13 In addition, many epilepsy patients may 
also have cognitive problems in addition to suffering from 
seizures,14–16 with the most common cognitive problem being 
memory deficit.2,17 While the causes of reduced memory func-
tions in patients with epilepsy have not yet been completely 
elucidated, the forms and frequencies of seizures and the side 
effects of AEDs at therapeutic doses have been described.18–22 
Consequently, the ideal AED should alter epileptogenesis, 
suppress seizures, and improve the concomitant cognitive 
impairments. Interestingly, the role of central histaminergic 
system involved in epilepsy is driven by growing indications of 
experimental outcomes that lead to the suggestion that central 
histamine controls seizure predisposition and thus functions 
as an anticonvulsant neurotransmitter in electrically as well as 
chemically induced seizure models in animals.4–17 Moreover, 
the precursor of histamine, namely the amino acid L-histidine, 
has been found to reduce chemically induced seizure in rats, as 
it triggers central histaminergic system and increases seizure 
threshold and decreases seizure tendency mediated by post-
synaptically located histamine H1 receptors (H1Rs).12,17,18 
Comparable experimental results were also observed in mice 
lacking histidine decarboxylase enzyme or H1Rs, demonstrat-
ing that the central H1Rs have been frequently linked to the 
development of seizures.27–29 Furthermore, it has been found 
that the clinical use of high doses of numerous centrally act-
ing H1R antagonists, eg, diphenhydramine, as anti-allergic 
drugs, occasionally stimulate a faster development of convul-
sions in healthy young children, particularly those receiving 
antihistamines for a long time.19,20 Similar preclinical results 
were observed in different animal seizure models, and fur-
ther support the link of brain histaminergic system to the 
pathophysiology of epileptic seizure.25,29
Histamine exerts its effects through binding to four 
G-protein-coupled H1-4R subtypes, and the H3R firstly 
described in 1983 was found to be a constitutively active 
receptor regularly expressed in the brain and pharmaco-
logically regulates histamine synthesis and release, acting as 
presynaptic autoreceptors.21,22 Consequently, ligands capable 
of increasing central histamine levels, such as histidine and 
histamine N-methyl transferase inhibitors (eg, metoprine), 
were found to decrease seizures in epileptic patients through 
H1R stimulation.12,17,23,24 Therefore, pharmacological profile 
of H3R antagonists as future anticonvulsant drugs has begun 
to attract increased consideration as growing experimental 
evidence from both acute and chronic models of epilepsy 
indicated efficiency of H3R antagonists.36,37 Accordingly, 
both imidazole and non-imidazole histamine H3R antago-
nists provided some protection in the maximal electroshock 
(MES)-induced convulsion in Wistar rats.11–16 Amongst 
numerous active H3R antagonists produced in both academia 
and industry, pitolisant (PIT, Bioprojet Biotech), with a 
marketed application (WakixR), was approved in November 
2015 by the European Medical Agency as an orphan drug 
for narcolepsy.12,25–27 Also, PIT tested in doses of 20, 40, and 
60 mg/kg significantly suppressed photosensitive epilepsy 
in ~64% of investigated patients.28 Moreover, and in pursuit 
of potent histamine H3R antagonists, our research group 
recently succeeded to develop a series of imidazole hista-
mine H3R antagonists having higher antagonist affinities for 
human histamine H3Rs than the previous H3R antagonists. 
One such compound, the imidazole-based H3R antagonist 
2-18, dose dependently demonstrated significant protection 
in MES-induced convulsion model in male adult Wistar rats 
(Figure 1).29 Moreover, subeffective dose of H3R antagonist 
2-18 (5 mg/kg, intraperitoneal [i.p.]) significantly potenti-
ated the protective effect in rats pretreated with the standard 
AED phenytoin (5 mg/kg, i.p.), a dose without appreciable 
protective action when given alone.16 Given their localization 
and their ability to modulate several central neurotransmitter 
systems and as a continuation of our research, the H3R 
antagonist 2-18 with high in vitro H3R antagonist affinity, 
excellent in vitro selectivity profile, and high in vivo H3R 
antagonist potency was investigated in the current study on 
its anticonvulsant effects in MES-induced convulsion models 
in adult mice of both sexes. Moreover, the H3R antagonist 
Figure 1 Chemical structure, in vitro affinities, and in vivo H3R antagonist potency 
of 2-18.
Note: Values previously published.56
Abbreviations: eD50, effective dose affecting 50% of mice receiving the compound 
2-18; p.o., peroral.
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2-18 was assessed for its reproductive toxicity in the same 
animal species following its systemic administration in a 
wide range of doses.
Materials and methods
animals
All experiments were performed in adult (age of 8–10 weeks) 
Tuck-Ordinary “TO” mice of both sexes weighing 30–35 g 
(Harlan, UK).57,58 The mice were group housed in standard 
Plexiglas observation cages in the central animal facility of 
College of Medicine and Health Sciences on a 12-h light/dark 
cycle (lights on at 6:00 am). Food and water were available ad 
libitum. The experiments of the current study were carried out 
between 9:00 and 12:00 h, and all procedures were performed 
according to the guidelines of the European Communities Coun-
cil Directive of November 24, 1986 (86/609/EEC) and were 
previously approved for epilepsy and teratogenic studies by 
College of Medicine and Health Sciences/United Arab Emirates 
University (Institutional Animal Ethics Committee, approval 
number; ERA-2017-5535 and A14-14, respectively).
Drugs
H3R agonist RAMH (10 mg/kg, i.p.) and valproic acid (VPA) 
were purchased from Sigma-Aldrich (St Louis, Missouri, 
USA). The H3R antagonist 2-18 was synthesized by the 
Department of Technology and Biotechnology of Drugs 
(Kraków, Poland) as described previously (Figure 1).29,51 
Accordingly, the carbamate derivative 2-18 was prepared 
from the appropriate amine by its reaction with excess of 
diphosgene, forming an intermediate isocyanate, which 
subsequently reacted with 3-(1H-imidazol-4-yl)propanol to 
furnish the desired product, namely 2-18. For the in vivo stud-
ies, test compound 2-18, VPA, and RAMH were dissolved in 
isotonic saline and administered i.p. at a volume of 1 mL/kg. 
Doses of H3R antagonist (7.5, 15, 30, and 60 mg/kg, i.p.) 
and RAMH (10 mg/kg, i.p.) were expressed in terms of the 
free base. For each test compound, a group of eight animals 
was used for the anticonvulsant study.
Mes-induced seizure
As previously described, the convulsions were induced in mice 
with a 50 Hz alternating current of 120 mA intensity.10,11,13–16,30,31 
The current was applied through ear electrodes for 1 s. Pro-
tection against the spread of MES-induced convulsion was 
defined as the abolition of the tonic hind limb extension 
(THLE) component of the convulsion.10,11,13,15,32,33 The animals 
were divided into groups of eight mice. In the positive control 
group, mice were injected with VPA at a previously described 
dose of 300 mg/kg, this being the minimal dose of VPA 
that protected animals against the spread of MES-induced 
convulsions without mortality in mice.34–38 Animals in the 
experimental groups were administered test compound 2-18 
at doses of 7.5, 15, 30, or 60 mg/kg, i.p. 30–45 min before 
the MES challenge. In a further experiment, a separate group 
of eight mice received two injections: the first injection 
contained the most effective dose of H3R antagonist 2-18 
and was administered 30 min prior MES challenge, and the 
second injection containing RAMH (10 mg/kg, i.p.) was 
administered 15 min prior the MES challenge.
statistics
For statistical comparisons, the software package SPSS 24.0 
(IBM Middle East, Dubai, UAE) was used. All data were 
expressed as means ± standard error of mean. The effects of 
H3R antagonist 2-18 on duration of THLE induced in male 
or female adult mice were analyzed using Kruskal–Wallis test 
with treatment (saline or test compound). The nonparametric 
Kruskal–Wallis test was used instead of the one-way ANOVA 
because the data were not normally distributed. The later 
was tested using Shapiro–Wilk test. Pairwise comparisons 
of anticonvulsant effect of H3R antagonist 2-18 between 
different groups or between male and female adult mice were 
analyzed using Mann–Whitney test to assess whether there 
was a significant difference in the duration of THLE between 
male and female adult mice. The sample size of test groups 
was small (n=8), therefore a power analysis for male as well as 
the female mice group was performed and the statistical results 
showed a beta value of greater than 0.85 (the null hypothesis 
was correctly [85%] rejected for the observed results). In all 
the tests, criterion for statistical significance was P,0.05.
reproductive studies
Adult female mice, about 30 g in weight and about 6 weeks 
of age, were mated with males in the evening, and vaginal 
plugs identified in the following morning were taken to 
indicate successful mating. Plug positive day was regarded 
as day 0 of gestation. Throughout the study, animals of 
all groups had free access to a commercial chow, and tap 
water was provided ad libitum. Animals were administered 
with different doses of H3R antagonist 2-18 (7.5, 15, 30, 
and 60 mg/kg, i.p.) and another group of animals received 
three injections containing 15 mg/kg at 3 hour intervals on 
gestation day (GD) 8, and to other similar groups of mice 
on GD 13 (Table 1). Also, similar number of groups of mice 
(n=8) were treated orally with H3R antagonist 2-18 (7.5, 
15, 30, and 60 mg/kg). The control groups were injected 
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with a proportionate volume of saline (i.p.), and daily food 
and water consumption by mice in the control groups were 
recorded. All animals were sacrificed by cervical dislocation 
on GD 18, and the embryos and placentae were collected. 
Implantation and resorption sites were noted. The fetuses 
were blotted dry and weighed and fixed in 95% ethanol and 
examined for gross and visceral malformations according to 
Sterz and Lehmann’s method.39
Method of whole embryo observation
The internal malformations were observed by a modified 
method of Sterz and Lehmann.39 The embryos were removed 
from the 95% ethanol and observed for any abnormalities 
with a stereo dissecting microscope by cutting the lower part 
of the abdomen using a razor blade. All organs were checked 
and removed by using forceps.
Double staining methods
Fetuses, without the viscera and skin, were placed in acetone 
for 1–3 days to eliminate the fat, following which they were 
stained at 37°C for 2–3 days (0.3% filtered alcian blue, 0.1% 
filtered alizarin red-S, acetic acid, 70% ethanol), and washed 
in water to be cleared of their soft tissues in 0.1% solution of 
potassium hydroxide until the skeleton was clearly visible. 
Then the cleared embryos were placed in an aqueous solution 
of 20% glycerin containing 1% KOH for 1–5 days. The clear 
specimens were placed through 50% and 80% glycerin, and 
stored in 100% glycerin to observe the malformations with 
a stereo dissecting microscope. They were then processed 
and stained with alizarin red-S and alcian blue for detecting 
bone and cartilage malformations.
Results
anticonvulsant effect of h3r antagonist 
2-18 in Mes-induced convulsion model 
in male adult mice
The protective activities of acute systemic administration 
of H3R ligand 2-18 on MES-induced convulsions in male 
adult mice were examined (Figure 2). The results showed 
that pretreatment with VPA and H3R antagonist 2-18 (7.5, 
15, 30, and 60 mg/kg, i.p.) exhibited a significant protective 
effect against MES-induced convulsions as confirmed by 
applying the Kruskal–Wallis test (H
(7)
 =47.65; P,0.001). 
Pairwise analyses of results showed that male adult mice 
pretreated with 7.5 mg/kg of H3R antagonist 2-18 were 
not protected against convulsions when compared with the 
saline-treated group with U=39.50 and P=0. 441 (Figure 2). 
However, substantial amplifications of protective effects 
were observed upon acute systemic injection with 15, 30, 
and 60 mg/kg of H3R antagonist 2-18 when compared 
with saline- or 2-18 (7.5 mg)-treated groups (all P-val-
ues ,0.001) (Figure 2). Notably, the protection provided 
by H3R antagonist 2-18 at the higher dose (60 mg/kg, i.p.) 
was comparable to that provided by the reference drug 
VPA with U=28.00 and P=0.721 (Figure 2). Moreover, 
the reversal of protection provided by H3R antagonist 
2-18 was examined and confirmed by co-injection with 
the potent and selective CNS-penetrant histamine H3R 
agonist RAMH (10 mg/kg, i.p.) 15 min before MES chal-
lenge (U=50.00 P=0.07, for the comparison of saline–
saline vs 2-18+ RAMH) (Figure 2). Furthermore, RAMH 
(10 mg/kg, i.p.) when injected alone did not affect MES-
induced convulsions (U=46.50 and P=0.13 saline + saline 
vs saline + RAMH) (Figure 2).
anticonvulsant effect of h3r antagonist 
2-18 in Mes-induced convulsion model 
in female adult mice
Similarly, the protective effects of acute systemic admin-
istration of H3R ligand 2-18 on MES-induced convulsions 
in female adult mice were examined (Figure 3). The results 
showed that pretreatment with VPA and H3R antagonist 
2-18 (7.5, 15, 30, and 60 mg/kg, i.p.) displayed a significant 
Figure 2 anticonvulsant effect of acute systemic administration of h3r antagonist 
2-18 on Mes-induced seizure in male adult mice.
Notes: anticonvulsant effects of VPa (300 mg/kg, i.p.), test compound 2-18 (7.5, 
15, 30, and 60 mg/kg, i.p.), and co-injection of test compound 2-18 (60 mg/kg, i.p.) 
with raMh (10 mg/kg, i.p.) on duration of Thle induced in Mes model in male adult 
mice. each value represents mean ± seM (n=8). ***P,0.001 versus saline- and 2-18 
(7.5 mg)-treated groups. #P,0.001 versus 2-18 (7.5 mg)- and 2-18 (15 mg)-treated 
groups. $P,0.05 versus 2-18 (30 mg)-treated group.
Abbreviations: Mes, maximal electroshock; VPa, valproic acid; i.p., intraperitoneal; 
raMh, R-(α)-methylhistamine; Thle, tonic hind limb extension; sal, saline; seM, 
standard error of mean.
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protection against MES-induced convulsions as confirmed 
by applying Kruskal–Wallis test (H
(7)
 =40.51; P,0.001). 
Pairwise analysis of variance showed that H3R antagonist 
2-18 at a dose of 60 mg/kg significantly exhibited the highest 
protective effect in MES model in female adult mice when 
compared with the saline- and 2-18 (7.5 mg)-treated group 
with (all P,0.05) (Figure 3). However, no significant differ-
ences were found between 2-18 (60 mg)-treated group and 
2-18 (15 mg)- or 2-18 (30 mg)-treated group with P=0.23 
and P=0.73, respectively. Moreover, the results revealed 
that female adult mice pretreated with 7.5 mg/kg of H3R 
antagonist 2-18 were not protected against MES convulsions 
when compared with the saline-treated group with U=29.00 
and P=0.798 (Figure 3). Similar to the results observed in 
male adult mice, the protection provided by H3R antagonist 
2-18 at the higher dose (60 mg/kg, i.p.) was comparable to 
that provided by the reference drug VPA with U=20.00 and 
P=0.234 (Figure 3). Moreover, the 2-18 (60 mg)-provided 
protection was completely abrogated by acute systemic co-
administration of the potent and selective CNS-penetrant 
histamine H3R agonist RAMH (10 mg/kg, i.p.) 15 min before 
MES challenge (U=45.50 and P=0.161, for the comparison of 
saline + saline vs 2-18 [60 mg] + RAMH) (Figure 3). Analy-
ses of data characterizing the protective effects of RAMH in 
female mice when injected alone (10 mg/kg, i.p.; U=44.00 
and P=0.234 saline–saline vs saline-RAMH) yielded results 
similar to those observed in male mice (Figure 3).
comparison of h3r antagonist 
2-18-provided anticonvulsant effect in 
Mes-induced convulsion model in male 
and female adult mice
The influence of the sex on the 2-18-provided anticonvulsant 
effect was assessed using Mann–Whitney test. Pairwise 
analyses of the observed results showed that there were no 
significant differences among tested groups with U=24.50 
(P=0.418), U=31.00 (P=0.913), U=31.00 (P=0.913), U=19.00 
(P=0.168), U=16.00 (P=0.084), and U=28.00 (P=0.629) for 
saline-, VPA-, 2-18 (7.5 mg)-, 2-18 (15 mg)-, 2-18 (30 mg)-, 
and 2-18 (60 mg)-treated groups of both sexes (Figure 4).
results of reproductive studies
There was no increased incidence of gross morphological 
anomalies in the treated fetuses of the single- and multiple-
dose groups given i.p. and orally when compared to the 
control group. The incidence of exencephaly and craniofacial 
malformations such as mandibular and maxillary hypoplasia, 
low set microtia, exophthalmia, exomphalos, eye remaining 
open, posterior bilateral palate, posterior unilateral palate, 
hydronephrosis, descended kidney, kinky tail, and unde-
scended testis was not significantly different in any of the 
groups studied (Table 1).
Figure 3 anticonvulsant effect of acute systemic administration of h3r antagonist 
2-18 on Mes-induced seizure in female adult mice.
Notes: anticonvulsant effects of VPa (300 mg/kg, i.p.), test compound 2-18 (7.5, 
15, 30, and 60 mg/kg, i.p.), and co-injection of test compound 2-18 (60 mg/kg, i.p.) 
with raMh (10 mg/kg, i.p.) on duration of Thle induced in Mes model in female 
adult mice. each value represents mean ± seM (n=8). ***P,0.001 versus saline- and 
2-18 (7.5 mg)-treated groups. #P,0.001 versus 2-18 (7.5 mg)- and 2-18 (15 mg)-
treated groups. $P,0.05 versus 2-18 (30 mg)-treated group. &Full protection.
Abbreviations: Mes, maximal electroshock; VPa, valproic acid; i.p., intraperitoneal; 
raMh, R-(α)-methylhistamine; Thle, tonic hind limb extension; sal, saline; seM, 
standard error of mean.
Figure 4 comparison of dose-dependent anticonvulsant effect of acute systemic 
administration of h3r antagonist 2-18 on Mes-induced seizure in male and female 
adult mice.
Notes: each value represents mean ± seM (n=8). &Full protection.
Abbreviations: Mes, maximal electroshock; Thle, tonic hind limb extension; 
VPa, valproic acid; sal, saline; seM, standard error of mean.
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There was no maternal mortality from the doses given. 
There were no abortions. Food and water consumption 
was the same in all groups. There was no difference in the 
numbers of litters or fetuses and placentae in the different 
groups. There were no differences between the weights of 
the fetuses and placentae per litter in all groups except in 
those administered 7.5 mg/kg of the drug i.p., which for some 
reason showed a significant reduction in weight (P,0.05). 
The saline control groups and the treatment groups had the 
same incidence of resorption and occurrence of intrauterine 
growth retardation. They did not differ in their mean fetal 
body weight. There was no dose-dependent reduction in fetal 
body weight even in the triple-dose groups (Tables 2 and 3).
skeletal malformations
skull defects
The experimental group skulls were normal in size compared 
to the controls (Table 4). Some of the treated group vault 
bases were poorly ossified but not significantly so. Maxilla 
and mandible were normal as compared to controls except 
for those in the early organogenesis period treated with 
low- and medium-dose groups. The supraoccipital bones 
of 78%–90% of the fetuses of the experimental group were 
at stage 5–6 as compared to 88%–90% control fetuses 
(Table 4). All fetuses had well-ossified bones. In the whole 
experiment, we found 0.2% fetuses that were exencephalic, 
all having defects of missing bones in the vault of the skull, 
and hypoplastic basicranial structures, ie, ethmoid, pres-
phenoid, basisphenoid, and basioccipital bones. Axillary-
mandibular hypoplasia was also present. They also had other 
skeletal defects of ilium, ischium, and pubis, and malfor-
mations of sacral and coccygeal vertebrae. All these were 
no different in the experimental embryos compared with 
the controls.
Vertebral defects
The vertebral column of full term mouse fetuses comprises 
seven cervical, 13 thoracic, six lumbar, six sacral, and vari-
able number of coccygeal arches. The centra were moderately 
fewer in number in i.p.-treated GD 8 group. The number 
Table 2 effect of h3r antagonist 2-18 treatment (i.p. or oral) in mouse embryos on gD 8 or 13
Saline control i.p. treatment on GD 8
7.5 mg/kg 15 mg/kg 30 mg/kg 60 mg/kg 15 mg/kg ×3 dose
number of litters 8 7 7 7 7 8
Fetuses/placentae/litter 10.500±0.535 10.429±0.976 10.000±0.816 10.143±0.678 9.714±0.756 10.968±0.926
live fetus/litter 9.658 (91.67) 9.429 (90.41) 9.143 (91.43) 9.429 (92.95) 9.000 (92.65) 9.875 (89.77)
resorption/litter 0.692 (6.49) 0.690 (10.61) 0.714 (7.81) 0.787 (7.81) 0.714 (7.94) 0.835 (11.39)
Fetal weight/litter (g)
(Mean ± sD) 1.269±0.024 1.231±0.025 1.239±0.036 1.258±0.027 1.293±0.031 1.259±0.074
iUgr-1sD 6/77 (7.79) 9/66 (13.64) 11/64 (17.18) 8/66 (12.12) 4/63 (6.35) 9/79 (11.39)
iUgr-2sD 3/77 (3.90) 7/66 (10.61) 5/64 (7.81) 4/66 (6.06) 3/63 (4.76) 8/79 (10.12)
Placental weight/litter (g)
(Mean ± sD) 0.097±0.002 0.091±0.002 0.097±0.009 0.093±0.007 0.097±0.009 0.092±0.010
iUgr-1sD 7/77 (9.09) 8/66 (12.12) 9/64 (14.06) 7/66 (10.74) 7/63 (11.11) 10/79 (12.66)
iUgr-2sD 2/77 (2.59) 4/66 (6.06) 5/64 (7.81) 4/66 (6.06) 3/63 (4.76) 5/79 (6.33)
Saline control i.p. treatment on GD 13
7.5 mg/kg 15 mg/kg 30 mg/kg 60 mg/kg 15 mg/kg ×3 dose
number of litters 7 7 7 7 8 8
Fetuses/placentae/litter 9.714±1.113 10.429±0.787 10.286±1.496 10.371±0.951 9.500±0.926 10.000±1.309
live fetus/litter 9.429 (97.06) 9.286 (89.04) 9.429 (91.67) 9.014 (91.89) 8.875 (93.42) 9.000 (90.00)
resorption/litter 0.429 (4.55) 0.714 (12.31) 0.857 (12.12) 0.857 (8.82) 0.500 (7.04) 0.875 (11.11)
Fetal weight/litter (g)
(Mean ± sD) 1.330±0.062 1.275±0.049 1.285±0.062 1.273±0.055 1.311±0.030 1.287±0.058
iUgr-1sD 6/66 (9.09) 9/65 (13.85) 8/66 (12.12) 8/68 (11.76) 6/71 (8.45) 11/72 (15.28)
iUgr-2sD 5/66 (7.58) 8/65 (12.30) 10/66 (15.15) 8/68 (11.76) 5/71 (7.04) 9/72 (12.50)
Placental weight/litter (g)
(Mean ± sD) 0.100±0.006 0.095±0.007 0.095±0.006 0.095±0.006 0.098±0.007 0.094±0.006*
iUgr-1sD 7/66 (10.60) 11/65 (16.92) 9/66 (13.63) 9/68 (13.23) 7/71 (9.86) 11/72 (15.28)
iUgr-2sD 5/66 (7.58) 8/65 (12.30) 6/66 (9.09) 8/68 (11.76) 6/71 (8.45) 9/72 (12.50)
Notes: *P,0.05, compared to the controls values (bold value). numerals in parentheses are percentages.
Abbreviations: i.p., intraperitoneal; gD, gestation day; iUgr, intrauterine growth retardation.
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of unossified/hypoplastic body was slightly increased in 
the early i.p.-induced and late gestation oral-treated groups 
but did not differ significantly from the controls (Table 5). 
Hemivertebrae and fusion of the centra in the thoracic, lum-
bar, and sacral segments were not observed. Hypoplastic or 
poor ossification of the caudal vertebrae number was slightly 
augmented in the experimental groups. There was a reduc-
tion in the number of coccygeal vertebral bodies observed 
in GD 8-treated fetuses.
rib defects
In both control and experimental fetuses, 13 pairs of thoracic 
ribs were observed giving a 2.6% incidence of cervical and 
lumbar ribs. The cervical ribs were attached to the seventh 
cervical vertebra and ended free anteriorly and were the first 
thoracic ribs. In the treated groups, cervical ribs were mod-
erately increased in number particularly in early gestation 
i.p.-induced group (Table 6). The lumbar ribs attached with 
the first lumbar vertebra were shorter than the last pair of the 
thoracic ribs. Incidence of lumbar ribs in the drug-treated 
group was not significantly different when compared to 
controls. There was no fusion of ribs, reduction in number 
and size, and splitting and forking of ribs in both control 
and treated groups.
sternal defects
The sternum of the control fetuses consisted of seven stern-
ebrae; the fifth sternebrum was moderately smaller in the late 
gestation-treated embryos. In about 97%–100% of fetuses, 
there were seven pairs of ribs. Absence or hypoplasia of the 
fifth sternebrum in the treated groups did not significantly 
differ from the controls (Table 6). We did not observe any 
malalignment, hemilateral or unilateral agenesis, scrambling, 
or fusion, but there were a few cases of bifid sternebrae in 
30 mg/kg i.p.-treated group embryos.
limb defects
There were no significant differences between the stages 
of limb development in any of the drug-administered mice 
fetuses when compared to the saline-administered mice 
Table 3 effect of h3r antagonist 2-18 treatment (i.p. or oral) in mouse embryos on gD 8 or 13
Saline control Oral treatment on GD 8
7.5 mg/kg 15 mg/kg 30 mg/kg 60 mg/kg 15 mg/kg ×3 dose
number of litters 8 8 8 8 8 8
Fetuses/placentae/litter 10.500±0.535 9.875±0.835 9.250±0.886 9.250±0.736 9.875±0.641 10.625±0.744
live fetus/litter 9.658 (91.67) 9.000 (91.14) 8.250 (89.19)* 8.375 (90.54) 9.250 (93.67) 9.625 (90.59)
resorption/litter 0.692 (6.49) 0.875 (9.72) 1.000 (12.12) 0.835 (10.45) 0.625 (6.75) 0.875 (10.38)
Fetal weight/litter (g)
(Mean ± sD) 1.269±0.024 1.253±0.084 1.262±0.054 1.252±0.032 1.277±0.036 1.265±0.079
iUgr-1sD 6/77 (7.79) 9/72 (12.50) 7/66 (10.61) 7/67 (10.44) 7/74 (9.46) 8/77 (10.38)
iUgr-2sD 3/77 (3.90) 6/72 (8.33) 6/66 (9.09) 5/67 (7.46) 4/74 (5.41) 6/77 (7.79)
Placental weight/litter (g)
(Mean ± sD) 0.097±0.002 0.095±0.008 0.096±0.009 0.093±0.006 0.094±0.008 0.094±0.007
iUgr-1sD 7/77 (9.09) 7/72 (9.72) 8/66 (12.12) 8/67 (11.94) 6/74 (8.10) 7/77 (9.09)
iUgr-2sD 2/77 (2.59) 6/72 (8.33)* 5/66 (7.56) 5/67 (7.46) 4/74 (5.41) 5/77 (6.49)
Saline control Oral treatment on GD 13
7.5 mg/kg 15 mg/kg 30 mg/kg 60 mg/kg 15 mg/kg ×3 dose
number of litters 7 8 8 8 8 7
Fetuses/placentae/litter 9.714±1.113 9.750±1.035 10.000±1.195 9.500±1.069 9.500±0.926 10.857±1.345
live fetus/litter 9.429 (97.06) 9.000 (92.31) 9.250 (92.50) 9.125 (92.10) 9.000 (94.74) 10.143 (93.42)
resorption/litter 0.429 (4.55) 0.750 (8.33) 0.750 (8.11) 0.750 (8.57) 0.500 (5.55) 0.571 (7.04)
Fetal weight/litter (g)
(Mean ± sD) 1.330±0.062 1.261±0.057* 1.282±0.056 1.273±0.052 1.301±0.090 1.273±0.077
iUgr-1sD 6/66 (9.09) 10/72 (13.88) 8/74 (10.81) 8/70 (11.42) 7/72 (9.72) 10/71 (14.08)
iUgr-2sD 5/66 (7.58) 7/72 (9.72) 7/74 (9.46) 6/70 (8.57) 7/72 (9.72) 9/71 (12.68)
Placental weight/litter (g)
(Mean ± sD) 0.100±0.006 0.093±0.005* 0.090±0.007* 0.094±0.007 0.094±0.006 0.089±0.006*
iUgr-1sD 7/66 (10.60) 11/72 (15.28) 11/74 (14.86) 9/70 (12.85) 8/72 (11.11) 7/71 (9.86)
iUgr-2sD 5/66 (7.58) 8/72 (11.11) 8/74 (10.81) 7/70 (10.00) 7/72 (9.72) 9/71 (12.68)
Notes: *P,0.05, compared to the controls values (bold values). numerals in parentheses are percentages.
Abbreviations: i.p., intraperitoneal; gD, gestation day; iUgr, intrauterine growth retardation.
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Table 4 h3r antagonist 2-18-induced skull abnormalities in mouse fetuses
Saline GD 8 (i.p. treated) GD 8 (orally treated)
7.5 mg 15 mg 30 mg 60 mg 15×3 mg 7.5 mg 15 mg 30 mg 60 mg 15×3 mg
no of skeletons 
examined
42 38 37 40 38 36 37 39 41 38 42
hypoplastic
Mandible 2 (4.8) 3 (7.9) 2 (5.4) 4 (10.0)* 2 (5.3) 3 (8.3) 2 (5.4) 2 (5.1) 2 (4.9) 2 (5.3) 3 (7.1)
Maxilla 2 (4.8) 3 (7.9) 2 (5.4) 4 (10.0)* 2 (5.3) 3 (8.3) 2 (5.4) 2 (5.1) 2 (4.9) 2 (5.3) 3 (7.1)
Zygomatic 1 (2.4) 2 (5.3) 1 (2.7) 1 (2.5) 1 (2.6) 1 (2.8) 2 (5.4) 1 (2.6) 2 (4.9) 1 (2.6) 1 (2.4)
nasal 1 (2.4) 2 (5.3) 1 (2.7) 1 (2.5) 1 (2.6) 2 (5.6) 1 (2.7) 1 (2.6) 2 (4.9) 1 (2.6) 2 (4.8)
Frontal 2 (4.8) 3 (7.9) 2 (5.4) 2 (5.0) 2 (5.3) 2 (5.6) 3 (8.1) 3 (7.7) 2 (4.9) 2 (5.3) 2 (4.8)
Parietal 1 (2.4) 2 (5.3) 2 (5.4) 2 (5.0) 1 (2.6) 1 (2.8) 2 (5.4) 2 (5.1) 2 (4.9) 1 (2.6) 1 (2.4)
inter parietal 1 (2.4) 2 (5.3) 1 (2.7) 1 (2.5) 1 (2.6) 1 (2.8) 2 (5.4) 1 (2.6) 1 (2.4) 1 (2.6) 1 (2.4)
exoccipital 0 1 (2.6) 1 (2.7) 1 (2.5) 1 (2.6) 1 (2.8) 1 (2.7) 1 (2.6) 1 (2.4) 1 (2.6) 1 (2.4)
ethmoid 2 (4.8) 3 (7.9) 2 (5.4) 2 (5.0) 2 (5.3) 3 (8.3) 2 (5.4) 3 (7.7) 2 (4.9) 2 (5.3) 3 (7.1)
Presphenoid 1 (2.4) 2 (5.3) 2 (5.4) 1 (2.5) 1 (2.6) 2 (5.6) 2 (5.4) 2 (5.1) 1 (2.4) 1 (2.6) 1 (2.4)
Basis sphenoid 1 (2.4) 2 (5.3) 2 (5.4) 1 (2.5) 1 (2.6) 2 (5.6) 2 (5.4) 1 (2.6) 1 (2.4) 1 (2.6) 2 (4.8)
Basioccipital 1 (2.4) 2 (5.3) 2 (5.4) 1 (2.5) 1 (2.6) 1 (2.8) 2 (5.4) 1 (2.6) 1 (2.4) 1 (2.6) 1 (2.4)
Tympanic ring 1 (2.4) 2 (5.3) 2 (5.4) 2 (5.0) 1 (2.6) 1 (2.8) 2 (5.4) 2 (5.1) 1 (2.4) 1 (2.6) 1 (2.4)
hyoid 1 (2.4) 2 (5.3) 2 (5.4) 2 (5.0) 1 (2.6) 2 (5.6) 2 (5.4) 2 (5.1) 1 (2.4) 1 (2.6) 2 (4.8)
supraoccipital – stage
1–4 5 (11.9) 7 (18.4) 9 (24.3)* 6 (15.0) 5 (13.2) 6 (16.7) 7 (18.9) 7 (17.9) 6 (14.6) 4 (10.5) 7 (16.7)
5–6 37 (88.1) 31 (81.6) 28 (75.7) 34 (85.0) 33 (86.8) 30 (83.3) 30 (81.1) 32 (82.1) 35 (85.4) 34 (89.5) 35 (83.3)
hypoplastic 4 (9.5) 6 (15.8) 6 (16.2) 5 (12.5) 4 (10.5) 5 (13.9) 6 (16.2) 5 (12.8) 4 (9.8) 3 (7.9) 4 (9.5)
Ossicle
0–1 2 (4.8) 3 (7.9) 2 (5.4) 3 (7.5) 2 (5.3) 3 (8.3) 3 (8.1) 3 (7.7) 3 (7.3) 1 (2.6) 4 (9.5)
2 39 (92.9) 35 (92.1) 34 (91.9) 35 (87.5) 34 (89.5) 33 (91.7) 34 (91.9) 35 (89.7) 37 (90.2) 35 37 (88.1)
3 1 (2.4) 0 1 (2.7) 2 (5.0) 2 (5.3) 0 0 1 (2.6) 1 (2.4) 2 (5.3) 1 (2.4)
Saline GD 13 (i.p. treated) GD 13 (orally treated)
7.5 mg 15 mg 30 mg 60 mg 15×3 mg 7.5 mg 15 mg 30 mg 60 mg 15×3 mg
no of skeletons 
examined
39 40 42 36 40 38 38 43 41 38 37
hypoplastic
Mandible 2 (5.1) 3 (7.5) 3 (7.1) 2 (5.6) 2 (5.0) 3 (7.9) 3 (7.9) 3 (7.0) 3 (7.3) 2 (5.3) 3 (8.1)
Maxilla 2 (5.1) 3 (7.5) 3 (7.1) 2 (5.6) 2 (5.0) 3 (7.9) 5 (13.2)* 2 (4.7) 2 (4.9) 2 (5.3) 3 (8.1)
Zygomatic 1 (2.6) 1 (2.5) 2 (4.8) 1 (2.8) 1 (2.5) 1 (2.6) 2 (5.3) 1 (2.3) 2 (4.9) 1 (2.6) 1 (2.7)
nasal 1 (2.6) 2 (5.0) 2 (4.8) 1 (2.8) 1 (2.5) 2 (5.3) 2 (5.3) 2 (4.7) 2 (4.9) 1 (2.6) 2 (5.4)
Frontal 2 (5.1) 3 (7.5) 3 (7.1) 3 (8.3) 2 (5.0) 2 (5.3) 3 (7.9) 3 (7.0) 2 (4.9) 2 (5.3) 2 (5.4)
Parietal 1 (2.6) 2 (5.0) 2 (4.8) 2 (5.6) 1 (2.5) 2 (5.3) 2 (5.3) 2 (4.7) 2 (4.9) 1 (2.6) 1 (2.7)
inter parietal 1 (2.6) 2 (5.0) 2 (4.8) 1 (2.8) 1 (2.5) 2 (5.3) 2 (5.3) 2 (4.7) 1 (2.4) 1 (2.6) 2 (5.4)
exoccipital 1 (2.6) 2 (5.0) 2 (4.8) 1 (2.8) 1 (2.5) 1 (2.6) 1 (2.6) 1 (2.3) 1 (2.4) 1 (2.6) 2 (5.4)
ethmoid 1 (2.6) 2 (5.0) 3 (7.1) 2 (5.6) 2 (5.0) 3 (7.9) 2 (5.3) 3 (7.0) 2 (4.9) 2 (5.3) 3 (8.1)
Presphenoid 1 (2.6) 2 (5.0) 2 (4.8) 1 (2.8) 1 (2.5) 2 (5.3) 2 (5.3) 2 (4.7) 1 (2.4) 1 (2.6) 1 (2.7)
Basis sphenoid 1 (2.6) 2 (5.0) 2 (4.8) 1 (2.8) 1 (2.5) 2 (5.3) 2 (5.3) 1 (2.3) 2 (4.9) 1 (2.6) 2 (5.4)
Basioccipital 1 (2.6) 2 (5.0) 2 (4.8) 1 (2.8) 1 (2.5) 1 (2.6) 2 (5.3) 1 (2.3) 1 (2.4) 1 (2.6) 1 (2.7)
Tympanic ring 1 (2.6) 2 (5.0) 2 (4.8) 2 (5.6) 1 (2.5) 1 (2.6) 2 (5.3) 2 (4.7) 2 (4.9) 2 (5.3) 1 (2.7)
hyoid 2 (5.1) 2 (5.0) 2 (4.8) 2 (5.6) 1 (2.5) 2 (5.3) 2 (5.3) 2 (4.7) 1 (2.4) 1 (2.6) 2 (5.4)
supraoccipital – stage
1–4 4 (10.3) 9 (22.5)* 8 (19.0) 6 (16.7) 5 (12.5) 6 (15.8) 6 (15.8) 7 (16.3) 6 (14.6) 4 (10.5) 9 (24.3)*
5–6 35 (89.7) 31 (77.5) 34 (81.0) 30 (83.3) 35 (87.5) 32 (84.2) 32 (84.2) 36 (83.7) 35 (85.4) 34 (89.5) 35 (94.6)
hypoplastic 3 (7.7) 5 (12.5) 5 (11.9) 5 (13.9) 3 (7.5) 5 (13.2) 5 (13.2) 5 (11.6) 4 (9.8) 3 (7.9) 4 (10.8)
Ossicle
0–1 2 (5.1) 4 (10.0) 4 (9.5) 3 (8.3) 2 (5.0) 3 (7.9) 4 (10.5) 4 (9.3) 3 (7.3) 1 (2.6) 3 (8.1)
2 36 (92.3) 36 (90.0) 38 (90.5) 33 (91.7) 37 (92.5) 35 (92.1) 34 (89.5) 38 (88.4) 37 35 (92.1) 33 (89.2)
3 1 (2.6) 0 0 0 1 (2.5) 0 0 1 (2.3) 1 (2.4) 2 (5.3) 1 (2.7)
Notes: numerals in parentheses are percentages; *P,0.05, compared to the control values (bold values).
Abbreviations: i.p., intraperitoneal; gD, gestation day.
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Anticonvulsant effects and safety profile of H3R antagonist 2-18
fetuses (Table 7). However, in the eight GD, orally treated 
mice fetuses with the three-dose regimen, there were signifi-
cantly more 2-foot tarsals than the control fetuses. In addi-
tion, there was a significantly higher number of mice fetuses 
with 0–4 metatarsals on day 13 orally treated experimental 
group than there were in controls. All others were similar in 
all groups of mice.
In short, there were no significant differences in skeletal 
anomalies, vertebral defects, skull defects, rib defects, sternal 
defects, or limb defects in all the groups of mice studied. 
There were no anomalies of the internal organs.
Discussion
The results in the MES model showed that H3R antagonist 
2-18 provided the most encouraging protection against MES-
induced convulsions when animals were pretreated with 
60 mg/kg i.p., as compared with the saline-treated or lower 
dosed groups (Figures 1–3). Consequently, the observed 
results revealed a dose–response relationship of the protection 
provided for H3R antagonist 2-18 in the MES-induced con-
vulsions in adult mice of both sexes (Figures 1 and 2). Nota-
bly, the protective activity of H3R antagonist 2-18 (60 mg/kg, 
i.p.) was similar to that observed in the group pretreated with 
the reference AED VPA (500 mg/kg, i.p.) (Figures 1 and 2). 
The latter results are in agreement with recent preclinical out-
comes that showed a dose-dependent anticonvulsant activity 
of numerous H3R antagonists in MES-induced convulsions in 
several animal models and of PIT in a photosensitivity seizure 
model in adult patients.10–12,14–16,28 An additional experiment 
in the present study indicated that the protection observed 
for H3R antagonist 2-18 was reversed when animals were 
co-injected with the CNS-penetrant histamine H3R agonist 
RAMH (10 mg/kg i.p.) (Figure 1). Interestingly, RAMH 
(10 mg/kg) injected alone showed neither a protective nor 
an epileptogenic activity in animals challenged by the MES-
induced convulsion (Figures 1 and 2). These results propose 
that the protective activity of the H3R antagonist 2-18 in the 
MES-induced convulsion is facilitated, at least to some extent, 
through H3R blockade, and are in agreement with the previ-
ously observed protective efficacies for numerous imidazole 
as well as non-imidazole-based H3R antagonists.10–14,16,40 
Accordingly, H3Rs are autoreceptors located on presynap-
tic histaminergic terminals with an inhibitory effect on the 
biosynthesis and release of histamine into histaminergic 
synaptic gap.12 Therefore, H3R blockade by selective antago-
nists, such as compound 2-18, would produce an increased 
neuronal release of central histamine, providing the protec-
tive effect in the MES-induced convulsion mode in mice. ,
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Anticonvulsant effects and safety profile of H3R antagonist 2-18
Importantly, comparable effects of imidazole-based as well 
as non-imidazole-based H3R antagonists were previously 
described to be abrogated by either H3R agonists or CNS-
penetrant H1R or H2R antagonists, signifying an important 
role of the H3R antagonism-released histamine.10,14,16,40,41 
On the other hand, no significant differences were observed 
for the reference drug VPA (500 mg/kg, i.p.) and for all 
tested doses of the H3R antagonist 2-18 (7.5–60 mg/kg, 
i.p.) in both sexes of adult mice (Figure 4). The latter results 
are in disagreement with previous studies in which certain 
differences in seizure susceptibility were found between both 
sexes due to differences in levels of steroids and steroidal 
derivatives, eg, 3α-hydroxylated pregnane steroids, capable 
of interacting with GABA receptor complex, and therefore 
decreasing seizure susceptibility in female adult mice.42–45 
In a further set of experiments, we administered various doses 
Table 7 h3r antagonist 2-18-induced limb abnormalities in mouse fetuses
Saline GD 8 (i.p. treated) GD 8 (orally treated)
7.5 mg 15 mg 30 mg 60 mg 15×3 mg 7.5 mg 15 mg 30 mg 60 mg 15×3 mg
no of skeletons 
examined
42 38 37 40 38 36 37 39 41 38 42
hand – metacarpals
0–3 2 (4.8) 3 (7.3) 2 (5.4) 2 (5.0) 2 (5.3) 3 (8.3) 2 (5.4) 2 (5.1) 2 (4.9) 2 (5.3) 3 (7.1)
4–5 40 (95.2) 35 (92.1) 35 (94.6) 38 (95.0) 36 (94.7) 33 (91.7) 35 (94.6) 37 (94.9) 39 (95.1) 36 (94.7) 39 (92.9)
hypo 2 (4.8) 4 (10.5) 5 (13.5)* 4 (10.0) 2 (5.3) 3 (8.3) 3 (8.1) 4 (10.3) 4 (9.8) 2 (5.3) 4 (9.5)
Phalanges
0–5 3 (7.1) 3 (7.3) 3 (8.1) 4 (10.0) 2 (5.3) 3 (8.3) 3 (8.1) 3 (7.7) 5 (12.2) 3 (7.9) 3 (7.1)
6–10 5 (11.9) 6 (15.8) 6 (16.2) 7 (17.5) 5 (13.2) 6 (16.7) 4 (10.8) 4 (10.3) 4 (9.8) 4 (10.5) 5 (11.9)
11–12 34 (81.0) 29 (76.3) 28 (75.7) 29 (72.5) 31 (81.6) 27 (75.0) 30 (81.1) 32 (82.1) 32 (78.0) 31 (81.5) 33 (78.6)
Foot – tarsals
0 8 (19.0) 8 (21.1) 8 (21.6) 9 (22.5) 6 (15.8) 7 (19.4) 8 (21.6) 8 (20.5) 8 (19.5) 6 (15.8) 10 (23.8)
1 28 (66.7) 25 (65.8) 24 (64.9) 25 (62.5) 25 (65.8) 24 (66.7) 25 (67.6) 25 (64.1) 28 (68.3) 26 (68.4) 29 (69.0)
2 6 (14.3) 5 (13.2) 5 (13.5) 6 (15.0) 7 (18.4) 5 (13.9) 6 (16.2) 6 (15.4) 5 (12.2) 6 (15.8) 3 (7.1)*
Metatarsals
0–4 2 (4.8) 3 (7.9) 2 (5.4) 4 (10.0) 3 (7.9) 3 (8.3) 3 (8.1) 2 (5.1) 3 (7.3) 2 (5.3) 3 (7.1)
5 40 (95.2) 35 (92.1) 35 (94.6) 36 (90.0) 35 (92.1) 33 (91.7) 34 (91.9) 37 (94.3) 39 (95.1) 36 (94.7) 39 (92.9)
Phalanges
0–5 2 (4.8) 4 (10.5) 3 (8.1) 3 (7.5) 3 (7.9) 4 (11.0) 3 (8.1) 4 (10.3) 4 (9.8) 3 (7.9) 4 (9.5)
6–10 21 (50.0) 21 (55.3) 19 (51.4) 18 (45.0) 22 (57.9) 19 (52.8) 20 (54.1) 21 (53.8) 20 (48.8) 18 (47.4) 22 (52.4)
11–14 19 (45.2) 13 (34.2) 15 (40.5) 17 (42.5) 13 (34.2) 13 (36.1) 14 (37.8) 14 (35.9) 17 (41.5) 17 (44.7) 16 (38.1)
Saline GD 13 (i.p. treated) GD 13 (orally treated)
7.5 mg 15 mg 30 mg 60 mg 15×3 mg 7.5 mg 15 mg 30 mg 60 mg 15×3 mg
no of skeletons 
examined
39 40 42 36 40 38 38 43 41 38 37
hand – metacarpals
0–3 2 (5.1) 3 (7.5) 4 (9.5) 2 (5.6) 2 (5.0) 3 (7.9) 3 (7.9) 4 (9.3) 4 (9.8) 2 (5.3) 2 (5.4)
4–5 37 (94.9) 36 (90.0) 38 (90.5) 34 (94.4) 38 (95.0) 35 (92.1) 35 (92.1) 39 (90.7) 37 (90.2) 36 (94.7) 35 (94.6)
hypo 2 (5.1) 4 (10.0) 4 (9.5) 3 (8.3) 3 (7.5) 3 (7.9) 3 (7.9) 4 (9.3) 4 (9.8) 3 (7.9) 3 (8.1)
Phalanges
0–5 2 (5.1) 3 (7.5) 4 (9.5) 3 (8.3) 2 (5.0) 2 (5.3) 2 (5.3) 4 (9.3) 3 (7.3) 3 (7.9) 2 (5.4)
6–10 6 (15.4) 7 (17.5) 9 (21.4) 6 (16.7) 7 (17.5) 7 (18.4) 5 (13.2) 8 (18.60) 7 (17.1) 5 (13.2) 5 (13.5)
11–12 31 (79.5) 30 (75.0) 29 (69.0) 27 (75.0) 31 (77.5) 29 (76.3) 31 (81.6) 31 (72.1) 31 (75.6) 30 (78.9) 30 (81.1)
Foot – tarsals
0 5 (12.8) 6 (15.0) 9 (21.4)* 6 (16.7) 5 (12.5) 5 (13.2) 5 (13.2) 8 (18.6) 5 (12.2) 4 (10.5) 6 (16.2)
1 26 (66.7) 27 (67.5) 25 (59.5) 27 (75.0) 29 (72.5) 28 (73.7) 27 (71.1) 28 (65.1) 29 (70.7) 28 (73.7) 25 (67.6)
2 8 (20.5) 7 (17.5) 8 (19.0) 6 (16.7) 6 (15.0) 5 (13.2) 6 (15.8) 7 (16.3) 7 (17.1) 6 (15.8) 6 (16.2)
Metatarsals
0–4 2 (5.1) 3 (7.5) 4 (9.5) 3 (8.3) 3 (7.5) 3 (7.9) 3 (7.9) 5 (11.6) 4 (9.8) 3 (7.9) 5 (13.5)*
5 37 (94.9) 37 (92.5) 38 (90.5) 33 (91.7) 37 (92.5) 35 (92.1) 35 (92.1) 38 (88.4) 37 (90.2) 36 (94.7) 32 (86.5)
Phalanges
0–5 3 (7.7) 4 (10.0) 5 (11.9) 4 (11.1) 3 (7.5) 4 (10.5) 4 (10.5) 5 (11.6) 5 (12.2) 3 (7.9) 3 (8.1)
6–10 19 (48.7) 20 (50.0) 21 (50.0) 19 (52.8) 18 (45.0) 17 (44.7) 17 (44.7) 22 (51.2) 18 (43.9) 20 (52.6) 18 (48.6)
11–14 17 (43.6) 16 (40.0) 16 (38.1) 13 (36.1) 19 (47.5) 17 (44.7) 17 (44.7) 16 (37.2) 18 (43.9) 17 (44.7) 16 (43.2)
Notes: numerals in parentheses are percentages; *P,0.05, compared to the control values.
Abbreviations: i.p., intraperitoneal; gD, gestation day.
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of H3R antagonist 2-18 to groups of mice on GDs 8 and 13 
and found no difference in the abnormalities that occurred in 
the fetuses. All AEDs including the third-generation AEDs 
given to pregnant women have been shown to have deleteri-
ous effects on fetuses in numerous studies from all over the 
world.46–51 These effects could result in fetal loss, perinatal 
death, congenital malformations, hemorrhage, developmental 
delay, low birth weight, and other serious effects. Epileptic 
women have no choice but to continue to take AEDs during 
pregnancy. It is therefore important to develop a therapeutic 
agent that has a good seizure control and at the same time 
has a very low risk of side effects in the woman and in the 
fetus. The present compound, namely the H3R antagonist 
2-18, seems to fulfill both criteria and is a promising AED 
for use during pregnancy in the lowest doses that manage to 
control the epileptic fits. The doses of H3R antagonist 2-18 
used in the present study succeeded in controlling the fits and 
were not maternally toxic, as the food and water consumed 
by the mice were not affected. The mice also gained weight 
normally. These doses are suitable for mice but could be 
different in humans. Usually, mice receive much higher 
doses for the same condition than would humans, as direct 
extrapolations of doses of drugs from animals to humans on 
mg/kg basis cannot be achieved. There are species-specific 
differences in their metabolism, excretion, absorption, 
biotransformation, and pharmacokinetics.52,53 Therefore, 
calculations of doses cannot be made by simple mathematical 
equations. Small laboratory animals have high rates of 
metabolism and therefore use a larger dose for the same 
effect as that used in larger animals.54 Also, in pregnancy the 
pharmacokinetic parameters of an AED are altered, thereby 
requiring larger doses to produce the desired antiepileptic 
effect.55 There is not much information on the changes to the 
pharmacokinetics of H3R antagonist 2-18 during pregnancy. 
We administered H3R antagonist 2-18 during organogenesis 
(GD 8) as susceptibility to congenital malformations is great-
est during this period and during the fetal period (GD 13) 
where growth could be affected. Implantation of embryos 
was not affected and fetal losses were no different than in 
the saline-treated mice even in the higher dose of 60 mg/kg 
or in those given multiple doses of the drug. In comparison 
with other AEDs, the tested compound 2-18 does seem to 
have minimal teratological effects, but it should be tested over 
the whole course of pregnancy to ensure that no cumulative 
effects occur.
Conclusion
The results observed for H3R antagonist 2-18 in the current 
studies show that it has the potential of being a very effective 
AED and could also be used in pregnancy; however, more 
studies, in which H3R antagonist 2-18 is given over the entire 
course of gestation, are needed to assess whether these results 
could be replicated before this drug is approved.
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